# A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma

> **NCT02040779** · PHASE3 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 273 (actual)

## Conditions studied

- Persistent Asthma

## Interventions

- **DRUG:** Beclomethasone dipropionate breath-actuated inhaler
- **DRUG:** Placebo breath-actuated inhaler
- **DRUG:** albuterol/salbutamol

## Key facts

- **NCT ID:** NCT02040779
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-26
- **Primary completion:** 2014-12-24
- **Final completion:** 2014-12-24
- **Target enrollment:** 273 (ACTUAL)
- **Last updated:** 2021-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02040779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02040779, "A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02040779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*